123 related articles for article (PubMed ID: 9619197)
1. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
Sheean GL; Murray NM; Rothwell JC; Miller DH; Thompson AJ
Brain; 1998 May; 121 ( Pt 5)():967-75. PubMed ID: 9619197
[TBL] [Abstract][Full Text] [Related]
2. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Mainero C; Inghilleri M; Pantano P; Conte A; Lenzi D; Frasca V; Bozzao L; Pozzilli C
Neurology; 2004 Jun; 62(11):2044-50. PubMed ID: 15184612
[TBL] [Abstract][Full Text] [Related]
3. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Polman CH; Bertelsmann FW; de Waal R; van Diemen HA; Uitdehaag BM; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
[TBL] [Abstract][Full Text] [Related]
4. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
Bever CT; Leslie J; Camenga DL; Panitch HS; Johnson KP
Ann Neurol; 1990 Apr; 27(4):421-7. PubMed ID: 2353797
[TBL] [Abstract][Full Text] [Related]
5. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Flet L; Polard E; Guillard O; Leray E; Allain H; Javaudin L; Edan G
J Neurol; 2010 Jun; 257(6):937-46. PubMed ID: 20058019
[TBL] [Abstract][Full Text] [Related]
6. Analysis of 3,4-diaminopyridine in human serum by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
Leslie J; Bever CT
J Chromatogr; 1989 Nov; 496(1):214-22. PubMed ID: 2556419
[No Abstract] [Full Text] [Related]
7. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
Telford RJ; Hollway TE
Br J Anaesth; 1990 Mar; 64(3):363-6. PubMed ID: 1970263
[TBL] [Abstract][Full Text] [Related]
8. [Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Debouverie M; Pittion S
Rev Neurol (Paris); 2006 Mar; 162(3):295-7. PubMed ID: 16585884
[No Abstract] [Full Text] [Related]
9. The current status of studies of aminopyridines in patients with multiple sclerosis.
Bever CT
Ann Neurol; 1994; 36 Suppl():S118-21. PubMed ID: 8017870
[TBL] [Abstract][Full Text] [Related]
10. [Aminopyridines for symptomatic treatment of multiple sclerosis].
Jensen HB; Stenager E; Ravnborg MH
Ugeskr Laeger; 2011 Dec; 173(50):3259-63. PubMed ID: 22153210
[TBL] [Abstract][Full Text] [Related]
11. An electrophysiological study of the mechanism of fatigue in multiple sclerosis.
Sheean GL; Murray NM; Rothwell JC; Miller DH; Thompson AJ
Brain; 1997 Feb; 120 ( Pt 2)():299-315. PubMed ID: 9117377
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiology and treatment of fatigue in multiple sclerosis].
Boërio D; Lefaucheur JP; Hogrel JY; Créange A
Rev Neurol (Paris); 2006 Mar; 162(3):311-20. PubMed ID: 16585886
[TBL] [Abstract][Full Text] [Related]
13. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
[TBL] [Abstract][Full Text] [Related]
14. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
Bever CT; Anderson PA; Leslie J; Panitch HS; Dhib-Jalbut S; Khan OA; Milo R; Hebel JR; Conway KL; Katz E; Johnson KP
Neurology; 1996 Dec; 47(6):1457-62. PubMed ID: 8960727
[TBL] [Abstract][Full Text] [Related]
15. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):213-7. PubMed ID: 9703174
[TBL] [Abstract][Full Text] [Related]
16. Modafinil effects in multiple sclerosis patients with fatigue.
Lange R; Volkmer M; Heesen C; Liepert J
J Neurol; 2009 Apr; 256(4):645-50. PubMed ID: 19367356
[TBL] [Abstract][Full Text] [Related]
17. Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Bertorini TE; Rashed H; Zeno M; Tolley EA; Igarashi M; Li YD
J Clin Neuromuscul Dis; 2011 Mar; 12(3):129-37. PubMed ID: 21321491
[TBL] [Abstract][Full Text] [Related]
18. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.
Allart E; Benoit A; Blanchard-Dauphin A; Tiffreau V; Thevenon A; Zephir H; Outteryck O; Lacour A; Vermersch P
J Neurol; 2015 Aug; 262(8):1936-45. PubMed ID: 26041616
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation.
Van Lunteren E; Moyer M; Pollarine J
Muscle Nerve; 2008 Dec; 38(6):1616-22. PubMed ID: 19016549
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.
Palace J; Wiles CM; Newsom-Davis J
J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1069-72. PubMed ID: 1783919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
